| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | MS4A1 | Synonyms | B1, Bp35, CD20, CVID5, FMC7, LEU-16, S7 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Description | membrane spanning 4-domains A1 | ||||
| GTO ID | GTC3549 |
| Trial ID | NCT05990465 |
| Disease | Non-Hodgkin's Lymphoma | Diffuse Large B Cell Lymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Mantle Cell Lymphoma | Burkitt Lymphoma |
| Altered gene | CD19|CD20 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | LV20.19 CAR T cells |
| Co-treatment | Pirtobrutinib |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | Phase I Study of LV20.19 CAR T-cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies |
| Year | 2024 |
| Country | United States |
| Company sponsor | Medical College of Wisconsin |
| Other ID(s) | PRO00050826 |
| Cohort 1 | |||||||||||
|
|||||||||||